September 26, 2026 – Aspartes Pharmaceuticals Announces Completion of Phase 1 Clinical Study Evaluating ASP-001 ODT Formulations.
September 26, 2026 – Aspartes Pharmaceuticals Announces Completion of Phase 1 Clinical Study Evaluating ASP-001 ODT Formulations.
Aspartes Pharmaceuticals is dedicated to advancing innovative therapies for rare disorders with significant unmet need. Our mission is to transform the lives of patients and families by developing promising therapies supported by meaningful clinical experience and strong scientific rationale.
Aspartes Pharmaceuticals is advancing a robust pipeline of innovative therapies focused on rare disorders with unmet need.
Alternating Hemiplegia of Childhood
FDA Type C Meeting Scheduled
Alternating Hemiplegia of Childhood (AHC) is a rare genetic neurodevelopmental disorder characterized by recurrent episodes of temporary paralysis affecting one or both sides of the body, often beginning in infancy or early childhood. Episodes can last from minutes to days and are commonly accompanied by abnormal eye movements, dystonia, seizures, developmental delay, and other neurological symptoms. Aspartes Pharmaceuticals is developing ASP-001, a novel pediatric orally dispersible tablet formulation of flunarizine, that has the potential to become the first FDA-approved treatment specifically indicated for AHC.
Aspartes is advancing ASP-001, a pediatric-optimized orally disintegrating tablet formulation of flunarizine, through a focused development program for Alternating Hemiplegia of Childhood.
